With the end of the COVID-19 pandemic, healthcare providers have been directing most of their capabilities toward preventive healthcare and precision medicine, as the clinical diagnostics industry continues its transition from a centralized to a decentralized testing model. Globally, 2024 is set to be a profitable year for the industry, which will likely witness sustained growth through to 2029. The main growth drivers will be the point-of-care testing (POCT) and molecular diagnostics sectors, which the publisher expects to rebound even more strongly in 2024.Driven by Digital Services and Automation, the Molecular Diagnostics and POCT Sectors Rebound after the COVID-19 Pandemic
This study examines clinical diagnostics industry trends and growth projections from 2024 to 2029 across five global regions. It analyzes innovative in vitro diagnostics technologies and applications, major vendors to watch, and growth opportunities in the post-pandemic reality. The research also provides the top 5 predictions for 2024 related to the industry’s decentralization trend, the recovery of molecular diagnostics, and the higher investments in automated solutions and novel digital models.
Table of Contents
Analysis Highlights
Strategic Imperatives
Growth Environment
Macroeconomic Factors
Revenue Trends - 2024
Mergers and Acquisitions
Top 5 Predictions - 2024
Industry Snapshot - 2024
Clinical Chemistry and Immunoassays - 2024
Molecular Diagnostics - 2024
POCT - 2024
Tissue Diagnostics - 2024
Growth Opportunity Universe
Conclusions
Next Steps